Peptide double GLP-1 / glucagon receptor agonist derived from exendin-4. The present invention relates to the use of a combination of a GLP-1 / glucagon receptor agonist or a GLP-1 / glucagon receptor agonist agonist, optionally in combination with a GLP-1 / glucagon / GIP receptor agonist and a metabolic syndrome disorder comprising, for example, diabetes and obesity, Their medical use.
展开▼